[go: up one dir, main page]

ZA200703716B - Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level - Google Patents

Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level

Info

Publication number
ZA200703716B
ZA200703716B ZA200703716A ZA200703716A ZA200703716B ZA 200703716 B ZA200703716 B ZA 200703716B ZA 200703716 A ZA200703716 A ZA 200703716A ZA 200703716 A ZA200703716 A ZA 200703716A ZA 200703716 B ZA200703716 B ZA 200703716B
Authority
ZA
South Africa
Prior art keywords
temozolomide
patient
treating cancer
dosing regimen
cancer based
Prior art date
Application number
ZA200703716A
Other languages
English (en)
Inventor
Zong Chen
Winograd Benjamin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36168622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200703716(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200703716B publication Critical patent/ZA200703716B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA200703716A 2004-11-09 2007-05-08 Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level ZA200703716B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62625804P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
ZA200703716B true ZA200703716B (en) 2008-09-25

Family

ID=36168622

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703716A ZA200703716B (en) 2004-11-09 2007-05-08 Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level

Country Status (13)

Country Link
US (2) US20060100188A1 (xx)
EP (1) EP1830845A2 (xx)
JP (2) JP2008519584A (xx)
CN (1) CN101098696A (xx)
AU (1) AU2005304672B2 (xx)
BR (1) BRPI0517976A (xx)
CA (1) CA2585446A1 (xx)
MX (1) MX2007005581A (xx)
NO (1) NO20072931L (xx)
NZ (1) NZ554831A (xx)
TW (1) TW200630089A (xx)
WO (1) WO2006052976A2 (xx)
ZA (1) ZA200703716B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213142B2 (en) 2002-02-22 2005-11-10 Merck Sharp & Dohme Llc Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
WO2006052976A2 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
CN101370497B (zh) * 2006-01-17 2010-11-17 雅培制药有限公司 包含parp抑制剂和细胞毒性剂的联合产品及用途
NZ571693A (en) 2006-04-05 2011-12-22 Opko Health Inc Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
SG170838A1 (en) 2006-04-05 2011-05-30 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
US20070264672A1 (en) * 2006-05-09 2007-11-15 Bimalendu Dasmahapatra Development of a novel assay for mgmt (methyl guanine methyl transferase)
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
WO2008140724A1 (en) * 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
EA030808B1 (ru) * 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
AU2016246134B2 (en) 2015-04-10 2022-04-21 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
CN110408694A (zh) * 2018-04-26 2019-11-05 胤安国际（辽宁）基因科技股份有限公司 评估替莫唑胺在治疗脑胶质瘤患者的敏感性的新方法
US20220195440A1 (en) * 2019-03-28 2022-06-23 Thomas Jefferson University Methods for treating cancers using antisense
WO2023113538A1 (ko) * 2021-12-17 2023-06-22 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5876146A (en) * 1995-10-27 1999-03-02 General Electric Company Apparatus and methods for repairing jet pump diffusers in a nuclear reactor
US5786146A (en) * 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) * 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
NZ536302A (en) * 1999-03-30 2006-05-26 Schering Corp Cancer treatment regime with temozolomide
US6346524B1 (en) * 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide
AU2001272909A1 (en) * 2000-05-12 2001-11-20 Duke University Assessing levels of o6-alkylguanine-dna alkyltransferase in vivo
US6773897B2 (en) * 2000-09-29 2004-08-10 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
EP1332208A2 (en) * 2000-10-30 2003-08-06 Gene Logic, Inc. Partially double-stranded nucleic acids, methods of making, and use thereof
DE60144246D1 (de) * 2000-11-20 2011-04-28 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
WO2004038404A2 (en) * 2002-10-28 2004-05-06 Pharmacia Italia Spa Method for optimizing therapeutic efficacy of nemorubicin
WO2004086949A2 (en) * 2003-03-25 2004-10-14 John Wayne Cancer Institute Dna markers for management of cancer
WO2006052976A2 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule

Also Published As

Publication number Publication date
JP2008519584A (ja) 2008-06-12
AU2005304672B2 (en) 2010-03-11
MX2007005581A (es) 2007-05-23
CN101098696A (zh) 2008-01-02
EP1830845A2 (en) 2007-09-12
JP2011121960A (ja) 2011-06-23
BRPI0517976A (pt) 2008-10-21
WO2006052976A3 (en) 2006-08-17
US20090247598A1 (en) 2009-10-01
US20060100188A1 (en) 2006-05-11
AU2005304672A1 (en) 2006-05-18
TW200630089A (en) 2006-09-01
CA2585446A1 (en) 2006-05-18
NO20072931L (no) 2007-08-03
NZ554831A (en) 2009-10-30
WO2006052976A2 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
ZA200703716B (en) Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level
IL206984A0 (en) Analoges of benzoquinone-containing ansamycins for the treatment of cancer
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
GB0410725D0 (en) Pyrrolobenzodiazepine therapeutic agents
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IL210399A0 (en) Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody
IL164599A0 (en) Combination therapy for the treatment of cancer
AU2003234597A8 (en) Drug therapy for celiac sprue
IL164896A0 (en) Immunoconjugates for the treatment of tumours
AU2003212634A8 (en) Compounds useful in the treatment of cancer
EP1809265A4 (en) METHOD FOR THE TREATMENT OF SYNNUCLEOPATHIES
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
EP1651211A4 (en) COMBINATION OF MEDICAMENTS FOR THE TREATMENT OF NEOPLASMS
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
IL178827A0 (en) Use of reboxetine for the treatment of pain
GB2413203A8 (en) Handheld medical reference application with integrated dosage calculator
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
GB0400802D0 (en) Compounds for the treatment of disease
GB0415181D0 (en) Compounds for use in the treatment of infection
AU2003296545A8 (en) Use of a trpm8-activating substance for the treatment of tumours
HK1108382A (en) Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER